

|   |              |               |            |                    |
|---|--------------|---------------|------------|--------------------|
| <b>INFORMATION<br/>DISCLOSURE<br/>STATEMENT</b> | Docket No.   | 27693-01009   | Serial No: | <b>09/ 911,692</b> |
|   | Inventor(s): | D.R. ANDERSON | Examiner:  | R. Schwadron       |
|   | Filed:       | 25 July 2001  | Art Unit:  | 1644               |

### U.S. PATENT DOCUMENTS


| INITIAL | INDEX | DOCUMENT         | DATE      | NAME  | CLASS | SUB. | FILING DATE |
|---------|-------|------------------|-----------|-------|-------|------|-------------|
| M       | C1    | 2006/ 0034835 A1 | 16 Feb 06 | Adams | —     | —    |             |

### FOREIGN PATENT DOCUMENTS


| INITIAL | INDEX | DOCUMENT     | DATE      | COUNTRY | CLASS | SUB. | TRANSLATION |    |
|---------|-------|--------------|-----------|---------|-------|------|-------------|----|
|         |       |              |           |         |       |      | YES         | NO |
| W       | C2    | 2004/ 056312 | 08 Jul 04 | WO      | —     | —    |             |    |

### OTHER DOCUMENTS

| INITIAL | INDEX | CITATION   |
|---------|-------|--|
| dk      | C3    | Lowman, H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential Activities in a Series of Humanized Anti-CD20 Antibodies.  |
| w       | C4    | Polyak, M.J., et al. (2002) <i>Blood</i> 99: 3256-62. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. |

|  |   |   |
|--|---|---|
| EXAMINER   |  |  |
| Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant. |   |   |
| Form PTO-1449 (modified)   |   | SHEET 1 OF 1  |

|  |               |                      |                 |                      |
|--|---------------|----------------------|-----------------|----------------------|
| INFORMATION<br>DISCLOSURE<br>STATEMENT | Docket No.    | 27693-01009          | Application No. | 09/911,692           |
|  | Applicant(s): | ANDERSON, Darrell A. | Examiner:       | SCHWADRON, Ronald B. |
|  | Filing Date:  | 7/25/2001            | Group Art Unit: | 1644                 |



**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|  |     |  |
|--|-----|--|
| ✓ 35   | B1  | Chinn, et al. "Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma." Proceedings of the American Medical Association for Cancer Research, Volume 33, Abstract 2012, p. 337, 1992. |
|  | B2  | Classon, et al. "The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen." The Journal of Experimental Medicine, Volume 169, No. 4, pp. 1497-1502, 1989.   |
|  | B3  | DeNardo, et al. "Requirements for a Treatment Plan in System for Radioimmunotherapy." International Journal of Radiation Oncology Biology Physics, Volume 11, Number 2, pp. 335-348, 1985.   |
|  | B4  | Kaminski, et al. "Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with 131-I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses." Blood, Abstract 161, p. 162,   |
|  | B5  | Langmuir, "Radiommunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine and Biology, Volume 19, Number 2, pp. 213-225, 1992.   |
|  | B6  | Larson, et al. "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose <sup>131</sup> I-labeled Monoclonal Antibodies Administered to Man." Nuclear Medicine and Biology, Volume 16, No. 2, pp. 153-158, 1989.  |
|  | B7  | Leichner, et al. "Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles." Medical Physics, Volume 20, Number 2, Pt.2, pp. 529-534, 1993   |
|  | B8  | Leichner, et al. "Dosimetry and Treatment Planning in Radioimmunotherapy." Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 109-120, 1990.  |
|  | B9  | Link, et al. "A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody." The Journal of Immunology, Vol. 137, No. 9, pp. 3013-3018, 1986.   |
|  | B10 | Macey, et al. "A Treatment Planning Program for Radioimmunotherapy" Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 123-131, 1990.   |
| ✓  | B11 | Meredith, et al. "Dose Fractionation of Radiolabeled Antibodies in Patients with Metastatic Colon Cancer." Journal of Nuclear Medicine, Volume 33, Number 9, pp. 1648-1653, 1992.  |
| EXAMINER   |     | DATE CONSIDERED  |
| Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |     | 8/31/01  |
| Form PTO-A820 (also form PTO-1449)   |     | SHEET 1 OF 2   |

8/31/01



|   |                                    |                                |
|---|------------------------------------|--------------------------------|
| <b>INFORMATION<br/>DISCLOSURE<br/>STATEMENT</b> | Docket No. 27693-01009             | Application No. 09/911,692     |
|   | Applicant(s): ANDERSON, Darrell A. | Examiner: SCHWADRON, Ronald B. |
|   | Filing Date: 7/25/2001             | Group Art Unit: 1644           |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|       |     |   |
|-------|-----|---|
| ✓ M/S | B12 | Parker, et al. "Radioimmunotherapy of Human B-Cell Lymphoma with <sup>90</sup> Y-conjugated Antiidiotype Monoclonal Antibody." Cancer Research, Volume 50, No. 3, pp. 1022s-1028s, 1990.  |
|       | B13 | Pearson, et al. "Enhanced Therapeutic Efficacy of an Immunotoxin in combination with Chemotherapy against an Intraperitoneal Human Tumor Xenograft in Athymic Mice." Cancer Research Volume 49, No. 18, pp. 4990-4995, 1989.  |
|       | B14 | Press, et al. "Endocytosis and Degradation of Monoclonal of Antibodies Targeting Human B-Cell Malignancies" Cancer Research, Volume 49, No. 17, pp. 4906-4912, 1989.  |
|       | B15 | Press, et al. "Radiolabeled Antibody Therapy of Human B Cell Lymphomas." Immunobiology of Proteins and Peptides VI, Volume 303, pp. 91-96, 1991.  |
|       | B16 | Securities and Exchange Commission, Form S-1 Registration Statement, Filed 1991, IDEC Pharmaceuticals   |
|       | B17 | Senter, Peter D. "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy." The FASEB Journal, Vol. 4. pp. 188-193, 1990.  |
|       | B18 | Senter, et al. "Activation of Prodrugs by Antibody-Enzyme Conjugates" Immunobiology of Proteins and Peptides VI, Volume 303, pp. 97-105, 1991.  |
|       | B19 | Schwartz-Albiez, et al. "The B Cell-Associated CD37 Antigen (gp40-52) Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein." The Journal of Immunology, Vol. 140, No. 3, pp. 905-914, 1988.   |
|       | B20 | Sharkey, et al. "Biological Considerations for Radioimmunotherapy." Cancer Research, Volume 50, No. 3, pp. 964s-969s, pp. 1990.   |
|       | B21 | Stewart, et al. "Intraperitoneal <sup>131</sup> I- And <sup>90</sup> Y-Labelled Monoclonal Antibodies for Ovarian Cancer: Pharmacokinetics and Normal Tissue Dosimetry." International Journal of Cancer, Supplement 3, pp. 71-76, 1988.  |
|       | B22 | Uckun, et al. "Combined Ex Vivo Treatment with Immunotoxins and Mafosfamid: A Novel Immunochemotherapeutic Approach for Elimination of Neoplastic T Cells from Autologous Marrow Grafts." The Journal of Immunology, Vol. 134, No. 5, pp. 3504-3515, 1985.                      |
|       | B23 | Uckun, et al. "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein." Cancer Research , Volume 45, No. 1, pp. 69-75, 1985. |
| ✓     | B24 | Yokota, et al. "Synergistic Potentiation of in Vivo Antitumor Activity of Anti-Human T-Leukemia Immunotoxins by Recombinant $\alpha$ -Interferon and Daunorubicin." Cancer Research, Volume 50, No. 1, pp. 32-37, 1990.   |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |
| Form PTO-A820 (also form PTO-1449)  |                 |
| SHEET 2 OF 2  |                 |

|  |               |                         |  |
|--|---------------|-------------------------|--|
| <b>INFORMATION<br/>DISCLOSURE<br/>STATEMENT</b><br><del>SEARCHED</del><br><del>INDEXED</del><br><del>MAILED</del><br><del>SEP 8 0 2005</del><br><del>PATENT &amp; TRADEMARK OFFICE</del> | Docket No.    | 27693-1009              | Application No. 09/911,692               |
|  | Applicant(s): | ANDERSON,<br>Darrell R. | Examiner:<br><b>SCHWADRON, Ronald B.</b> |
|  | Filing Date:  | 7/25/2001               | Group Art Unit: 1644                     |
|  |               |                         |  |

#### U.S. PATENT DOCUMENTS

| Examiner Initial | REF | DOCUMENT NUMBER | DATE       | NAME               | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|------------------|-----|-----------------|------------|--------------------|-------|----------|------------------------------|
| MJ               | A1  | 4,975,278       | 12/4/1990  | Senter et al.      |       |          |                              |
|                  | A2  | 5,677,180       | 10/14/1997 | Robinson et al.    |       |          |                              |
|                  | A3  | 5,686,072       | 11/11/1997 | Uhr et al.         |       |          |                              |
|                  | A4  | 5,693,780       | 12/2/1997  | Newman et al.      |       |          |                              |
|                  | A5  | 5,721,108       | 2/24/1998  | Robinson et al.    |       |          |                              |
|                  | A6  | 5,843,398       | 12/1/1998  | Kaminski et al.    |       |          |                              |
|                  | A7  | 6,015,542       | 1/18/2000  | Kaminski et al.    |       |          |                              |
|                  | A8  | 6,090,365       | 7/18/2000  | Kaminski et al.    |       |          |                              |
|                  | A9  | 6,120,767       | 9/19/2000  | Robinson et al.    |       |          |                              |
|                  | A10 | 6,287,537       | 9/11/2001  | Kaminski et al.    |       |          |                              |
|                  | A11 | 6,565,827       | 5/20/2003  | Kaminski et al.    |       |          |                              |
|                  | A12 | 6,652,852       | 11/25/2003 | Robinson, et al.   |       |          |                              |
|                  | A13 | 6,893,625       | 5/17/2005  | Robinson et al.    |       |          |                              |
|                  | A14 | 2002-0009444    | 1/24/2002  | Grillo-Lopez       |       |          |                              |
|                  | A15 | 2002-0197255    | 12/26/2002 | Anderson et al.    |       |          |                              |
|                  | A16 | 2003-0021781    | 1/30/2003  | Anderson et al.    |       |          |                              |
|                  | A17 | 2003-0026804    | 2/24/2003  | Grillo-Lopez       |       |          |                              |
|                  | A18 | 2003-0082172    | 5/1/2003   | Anderson et al.    |       |          |                              |
|                  | A19 | 2003-0147885    | 8/7/2005   | Anderson et al.    |       |          |                              |
|                  | A20 | 2003-0206903    | 11/6/2003  | Grillo-Lopez       |       |          |                              |
|                  | A21 | 2004-0213784    | 10/28/2004 | Grilo-Lopez et al. |       |          |                              |
|                  | A22 | 2005-0163708    | 7/28/2005  | Robinson et al.    |       |          |                              |
|                  | A23 | 2005-0186205    | 8/25/2005  | Anderson et al.    |       |          |                              |


#### FOREIGN PATENT DOCUMENTS

|    | REF | DOCUMENT NUMBER | DATE     | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|----|-----|-----------------|----------|---------|-------|----------|-------------|----|
|    |     |                 |          |         |       |          | YES         | NO |
| MJ | A24 | WO 91/04320     | 4/4/1991 | WO      | —     | —        |             | X  |
| JM | A25 | WO 93/02180     | 2/4/1993 | WO      | —     | —        |             | X  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| <b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |
| Form PTO-A820 (also form PTO-1449)  |                 |
| SHEET 1 OF 3  |                 |

*[Handwritten signature]*

8/31/06




|  |                                       |                                   |
|--|---------------------------------------|-----------------------------------|
| INFORMATION<br>DISCLOSURE<br>STATEMENT | Docket No. 27693-1009                 | Application No. 09/911,692        |
|  | Applicant(s): ANDERSON,<br>Darrell R. | Examiner:<br>SCHWADRON, Ronald B. |
|  | Filing Date: 7/25/2001                | Group Art Unit: 1644              |

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|   |     |   |
|---|-----|---|
| ✓ | A26 | Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with <sup>131</sup> I-labeled Anti-T-Cell Antibodies." Cancer Research, 46, pp. 6223-6228, 1986.   |
| ✓ | A27 | Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." Cancer Research; 52, pp. 637-642, 1992.  |
|   | A28 | Biogen Idee v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. California, January 22, 2004). <span style="float: right;">already<br/>of record</span>   |
| ✓ | A29 | Chen, et al. "Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.  |
|   | A30 | Clark et al. "Role of the Bp35 cell surface polypeptide in human B-cell activation" Vol. 82; pp. 1776-1770, 1985  |
|   | A31 | Clark, et al. "Phase I Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." Journal Cellular Biochemistry Supp. 9A, p. 63, 1985  |
| ↓ | A32 | DeNardo, et al. "Fractionated Radioimmunotherapy of B-Cell Malignancies with <sup>131</sup> I-Lym-1." Cancer Research (Suppl.) 50, pp. 1014s-1016s, 1990.   |
|   | A33 | Idée Pharmaceuticals v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. California, October 14, 2003). <span style="float: right;">already<br/>of record</span>   |
| ✓ | A34 | Kaminski, et al. "Initial Clinical Radioimmunotherapy Results with <sup>131</sup> I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." Antibody Immunoconjugates, and Radiopharmaceuticals Vol. 5, No. 3 p. 345, 1992  |
|   | A35 | Kaminski, et al. "131-I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.   |
|   | A36 | Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine Biology Vol. 19, No. 2, pp. 213-225, 1992.   |
|   | A37 | Levy, et al. "Tumor Therapy with Monoclonal Antibodies." Federation Proceedings 42:9 pp. 2650-2656, 1983  |
|   | A38 | Macklis, et al. "Radiobiologic Studies of Low-Dose-Rate <sup>90</sup> Y-Lymphoma Therapy." Cancer Supplement, Vol. 73, No. 3, pp. 966-973, 1994.  |
| ↑ | A39 | Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody mAB) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." Interferon and Chronic Myelogenous Leukemia." Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535 |

|   |  |                 |         |
|---|--|-----------------|---------|
| EXAMINER  |  | DATE CONSIDERED | 8/31/01 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |  |                 |         |
| Form PTO-A820 (also form PTO-1449)  |  | SHEET 2 OF 3    |         |



|  |               |                         |                 |                      |
|--|---------------|-------------------------|-----------------|----------------------|
| INFORMATION<br>DISCLOSURE<br>STATEMENT | Docket No.    | 27693-1009              | Application No. | 09/911,692           |
|  | Applicant(s): | ANDERSON,<br>Darrell R. | Examiner:       | SCHWADRON, Ronald B. |
|  | Filing Date:  | 7/25/2001               | Group Art Unit: | 1644                 |


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

|     |     |   |
|-----|-----|---|
| (✓) | A40 | Maloney, et al. "Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells." Blood, Vol. 80, No. 6, pp. 1502-1510, 1992. |
|     | A41 | Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." Medical Oncology Tumor Pharmacother Vol. 8, No. 3, pp. 207-220, 1991.  |
|     | A42 | Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." Journal of Clinical Investigative, Vol. 67, pp. 134-140, 1981.   |
|     | A43 | Reilly, "Radioimmunotherapy of malignancies." Clinical Pharmacy, Vol. 10, pp. 359-375, 1991.  |
|     | A44 | Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.   |
|     | A45 | See-Lasley, et al. "HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981  |
|     | A46 | Senter, et al. "Enhancement of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." Cancer Research 49, pp. 5789-5792, 1989.                                  |
| (✓) | A47 | Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." The Journal of Immunology Vol. 125, No. 4, pp. 1678-1685, 1960.  |

|   |  |                 |         |
|---|--|-----------------|---------|
| EXAMINER  |  | DATE CONSIDERED | 8/31/06 |
| <b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609;<br>Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |  |                 |         |
| Form PTO-A820 (also form PTO-1449)  |  | SHEET 3 OF 3    |         |

MAY 27 2004  
U.S. PATENT & TRADEMARK OFFICE

| FORM PTO-1449 (modified)<br>To: U.S. Department of Commerce<br>(PW FORM PAT-1449)<br>Patent and Trademark Office   |    |   |              |   | Atty.<br>Dkt. No.          | M#   | Client Ref.                   |
|--|----|---|--------------|---|----------------------------|--|-------------------------------|
|  |    |   |              |   |                            | 0280646                                      | 1992-30-0029CP1C3             |
| <b>INFORMATION DISCLOSURE STATEMENT<br/>BY APPLICANT</b>   |    |   |              |   | Applicant: ANDERSON et al. |  |                               |
|  |    |   |              |   | Appln. No.: 09/911,692     |  |                               |
|  |    |   |              |   | Filing Date: July 25, 2001 |  |                               |
| Date: May 27, 2004   |    | Page <b>1</b> of <b>1</b>   |              |   |                            | Examiner: Schwadron, R. Group Art Unit: 1644 |                               |
| <b>U.S. PATENT DOCUMENTS</b>   |    |   |              |   |                            |  |                               |
| Examiner's Initials*   |    | Document Number   | Date MM/YYYY | Name<br>(Family Name of First Inventor) | Class                      | Sub Class                                    | Filing Date                   |
|  | AR |   |              |   |                            |  |                               |
|  | BR |   |              |   |                            |  |                               |
|  | CR |   |              |   |                            |  |                               |
|  | DR |   |              |   |                            |  |                               |
|  | ER |   |              |   |                            |  |                               |
|  | FR |   |              |   |                            |  |                               |
|  | GR |   |              |   |                            |  |                               |
|  | HR |   |              |   |                            |  |                               |
| <b>FOREIGN PATENT DOCUMENTS</b>  |    |   |              |   |                            |  |                               |
|  |    | Document Number   | Date MM/YYYY | Country                                 | Inventor Name              | English Abstract                             | Translation Readily Available |
|  | IR |   |              |   |                            |  |                               |
|  | JR |   |              |   |                            |  |                               |
|  | KR |   |              |   |                            |  |                               |
|  | LR |   |              |   |                            |  |                               |
|  | MR |   |              |   |                            |  |                               |
|  | NR |   |              |   |                            |  |                               |
|  | OR |   |              |   |                            |  |                               |
|  | PR |   |              |   |                            |  |                               |
| <b>OTHER</b>   |    |   |              |   |                            |  |                               |
| <i>WJS</i>   | QR | <i>Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).</i> |              |   |                            |  |                               |
| <i>WJR</i>   | RR | <i>Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).</i>     |              |   |                            |  |                               |
|  | SR |   |              |   |                            |  |                               |
|  | TR |   |              |   |                            |  |                               |
|  | UR |   |              |   |                            |  |                               |
|  | VR |   |              |   |                            |  |                               |
|  | WR |   |              |   |                            |  |                               |
|  | XR |   |              |   |                            |  |                               |
|  | YR |   |              |   |                            |  |                               |
|  | ZR |   |              |   |                            |  |                               |
| Examiner   |    |   |              | Date Considered:                        |                            | <i>8/31/04</i>                               |                               |
| *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. |    |   |              |   |                            |  |                               |

| FORM PTO-1449 (modified)<br>To: U.S. Department of Commerce<br>(PW FORM PAT-1449)<br>Patent and Trademark Office  |    |  |              |                                      | Atty.<br>Dkt. No.                            | M#               | Client Ref.                   |
|---|----|--|--------------|--------------------------------------|--|------------------|-------------------------------|
|   |    |  |              |                                      |  | 0280646          | 1992-30-0029CP1C3             |
| <b>INFORMATION DISCLOSURE STATEMENT<br/>BY APPLICANT</b><br><br><br>Date: March 18, 2004 Page 1 of 1 |    |  |              |                                      | Applicant: ANDERSON et al.                   |                  |                               |
|   |    |  |              |                                      | Appln. No.: 09/911,692                       |                  |                               |
|   |    |  |              |                                      | Filing Date: July 25, 2001                   |                  |                               |
|   |    |  |              |                                      | Examiner: Schwadron, R. Group Art Unit: 1644 |                  |                               |
| <b>U.S. PATENT DOCUMENTS</b>  |    |  |              |                                      |  |                  |                               |
| Examiner's Initials*  |    | Document Number  | Date MM/YYYY | Name (Family Name of First Inventor) | Class  | Sub Class        | Filing Date                   |
| (B)   | AR | 5,595,721  | 01/1997      | KAMINSKI                             | —  | —                |                               |
|   | BR | 5,439,665  | 08/1995      | HANSEN                               | —  | —                |                               |
|   | CR | RE 38,008  | 02/2003      | ABRAMS                               | —  | —                |                               |
|   | DR | 5,736,137  | 04/1998      | ANDERSON                             | —  | —                |                               |
|   | ER | 5,776,456  | 07/1998      | ANDERSON                             | —  | —                |                               |
|   | FR | 5,843,439  | 12/1998      | ANDERSON                             | —  | —                |                               |
|   | GR | 6,399,061  | 06/2002      | ANDERSON                             | —  | —                |                               |
|   | HR | 6,682,734  | 01/2004      | ANDERSON                             | —  | —                |                               |
| <b>FOREIGN PATENT DOCUMENTS</b>   |    |  |              |                                      |  |                  |                               |
|   |    | Document Number  | Date MM/YYYY | Country                              | Inventor Name                                | English Abstract | Translation Readily Available |
| (M)   | IR | WO 94/11026  | 05/1994      | PCT                                  | ANDERSON                                     |                  |                               |
|   | JR |  |              |                                      |  |                  |                               |
|   | KR |  |              |                                      |  |                  |                               |
|   | LR |  |              |                                      |  |                  |                               |
|   | MR |  |              |                                      |  |                  |                               |
| <b>OTHER</b>  |    |  |              |                                      |  |                  |                               |
| (A)   | NR | Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.   |              |                                      |  |                  |                               |
|   | OR | Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.   |              |                                      |  |                  |                               |
|   | PR | Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94. |              |                                      |  |                  |                               |
|   | QR |  |              |                                      |  |                  |                               |
|   | RR |  |              |                                      |  |                  |                               |
|   | SR |  |              |                                      |  |                  |                               |
|   | TR |  |              |                                      |  |                  |                               |
|   | UR |  |              |                                      |  |                  |                               |
| Examiner  |    |  |              | Date Considered: 8/31/06             |  |                  |                               |

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
 To: U.S. Department of Commerce  
 (PW FORM PAT-1449)  
 Patent and Trademark Office



|                   |         |                   |
|-------------------|---------|-------------------|
| Atty.<br>Dkt. No. | M#      | Client Ref.       |
|                   | 0280646 | 1992-30-0029CP1C3 |

Applicant: ANDERSON et al.

Appln. No.: 09/911,692

Filing Date: July 17, 2001

Date: November 21, 2003

Page 1 of 1

Examiner: Unassigned Group Art Unit: 1644

#### U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date |
|----------------------|-----------------|--------------|--------------------------------------|-------|-----------|-------------|
| MB                   | AR 6,183,744 B1 | 02/2001      | GOLDENBERG                           | —     | —         |             |
| WB                   | BR 6,306,393 B1 | 10/2001      | GOLDENBERG                           | —     | —         |             |
| CR                   |                 |              |                                      |       |           |             |
| DR                   |                 |              |                                      |       |           |             |
| ER                   |                 |              |                                      |       |           |             |
| FR                   |                 |              |                                      |       |           |             |

#### FOREIGN PATENT DOCUMENTS

|    | Document Number | Date MM/YYYY | Country | Inventor Name | English Abstract | Translation Readily Available |
|----|-----------------|--------------|---------|---------------|------------------|-------------------------------|
| GR |                 |              |         |               |                  |                               |
| HR |                 |              |         |               |                  |                               |
| IR |                 |              |         |               |                  |                               |
| JR |                 |              |         |               |                  |                               |
| KR |                 |              |         |               |                  |                               |
| LR |                 |              |         |               |                  |                               |

#### OTHER

|    |    |   |
|----|----|---|
| MG | MR | Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83. |
|    | NR | Kaminski, et al., "Radioimmundetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, Abstract No. 1051.                         |
|    | OR | Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37<sup>th</sup> Annual Meeting</i> , p. 852, Abstract No. 622.                   |
|    | PR | Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.          |
|    | QR | Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.  |
|    | RR | Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp.1696-1711.                          |
|    | SR |   |
|    | TR |   |
|    | UR |   |
|    | VR |   |

Examiner

Date Considered:

8/31/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



|                             |                |  |
|-----------------------------|----------------|--|
| Atty.<br>Dkt. No.           | M#             | Client Ref.                                  |
|                             | 037003-0280646 | 1992-30-0029CP1C3                            |
| Applicant: Anderson, et al. |                |  |
| Appln. No.: 09/911,692      |                |  |
| Filing Date: July 25, 2001  |                |  |
| Date: October 21, 2003      | Page 1 of 3    | Examiner: Schwadron, R. Group Art Unit: 1644 |

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: October 21, 2003

Page 1 of 3

#### U.S. PATENT DOCUMENTS

| Examiner's Initials* | Document Number | Date MM/YYYY | Name (Family Name of First Inventor) | Class | Sub Class | Filing Date (if appropriate) |
|----------------------|-----------------|--------------|--------------------------------------|-------|-----------|------------------------------|
| WBS                  | AR 5,500,362    | 03/1996      | Robinson, et al.                     | 435   | 7.23      |                              |
| WBS                  | BR 5,648,267    | 07/1997      | Reff                                 | 435   | 320.1     |                              |
|                      | CR              |              |                                      |       |           |                              |

#### FOREIGN PATENT DOCUMENTS

|     | Document Number | Date MM/YYYY | Country | Inventor Name     | English Abstract |    | Translation Readily Available |    |
|-----|-----------------|--------------|---------|-------------------|------------------|----|-------------------------------|----|
|     |                 |              |         |                   | Enclosed         | No | Enclos                        | No |
| WBS | DR 0 125 023 A1 | 11/1984      | EP      | Cabilly, et al.   |                  |    |                               |    |
|     | ER 0 125 023 B1 | 11/1984      | EP      | Cabilly, et al.   |                  |    |                               |    |
|     | FR 0 125 023 B2 | 03/2002      | EP      | Cabilly, et al.   |                  |    |                               |    |
|     | GR 0 173 494 A2 | 03/1986      | EP      | Morrison, et al.  |                  |    |                               |    |
|     | HR 0 274 394 A2 | 07/1988      | EP      | Robinson, et al.  |                  |    |                               |    |
|     | IR 0 274 394 A3 | 07/1988      | EP      | Robinson, et al.  |                  |    |                               |    |
|     | JR 0 451 216 B1 | 01/1996      | EP      | Queen, et al.     |                  |    |                               |    |
|     | KR 0 682 040 A1 | 11/1995      | EP      | Queen, et al.     |                  |    |                               |    |
|     | LR 0 682 040 B1 | 11/1995      | EP      | Queen, et al.     |                  |    |                               |    |
|     | MR WO 88/04936  | 07/1988      | WO      | Robinson, et al.  |                  |    |                               |    |
| WBS | NR WO 92/07466  | 05/1992      | WO      | Hellström, et al. |                  |    |                               |    |

#### OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

|     |  |  |
|-----|--|--|
| WBS | Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2, Can Res 28:1121-1125 (1968).   |  |
|     | Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, Can. Res. 27:2479-2482 (1967).  |  |
|     | Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, Blood 69(2):597-604 (1987)                                     |  |
|     | Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.  |  |
|     | Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, Blood 63(6):1424-1433 (1984)                                 |  |
|     | Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Hem. Onc. Clinics of N.A. 5(5):1013-1025 (1991).   |  |
|     | Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP), Cancer 50:1695 (1982). |  |
|     | Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, J. Exp. Med., 154:737-749 (1981)  |  |

M L

8/31/06

102

C103

OCT 21 2003

PATENT & TRADEMARK OFFICE

|  |  |  |  |
|--|--|--|--|
|  | Boulian, G.L. et al., Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312:643 (December 1984).  |  |  |
|  | Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on <sup>51</sup> Cr-labeled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and drugs, <i>Immunology</i> 14:181-189 (1968).                            |  |  |
|  | Buchsbaum, D.J., et al., A comparison of <sup>131</sup> I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> , 18:1033-1041 (1990) |  |  |
|  | Buchsbaum, D.J., et al., Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, <i>Cancer Research (Suppl.)</i> 50:993s-999s (1990)                                       |  |  |
|  | Buchsbaum, D.J., et al., Comparison of <sup>131</sup> I- and <sup>90</sup> Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> 25:629-638 (1993)                                   |  |  |
|  | Calvert, J.E., et al., Cellular events in the differentiation of antibody-secreting cells, <i>Seminars in Hematology</i> , 21(4):226-243 (1984)  |  |  |
|  | Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem.</i> 162:156-159 (1987).  |  |  |
|  | Clark, E.A., et al., Role of the Bp35 cell surface polypeptide in human B-cell activation, <i>Proc. Natl. Acad. Sci. USA</i> , 82:1766-1770 (1985)   |  |  |
|  | Cope, Antibody shows promise in treating B-cell lymphoma, <i>Oncology</i> , 8(4):100 (1994)  |  |  |
|  | DeNardo, S.J., et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1(1):17-33 (1988)  |  |  |
|  | DeNardo, S.J., et al., The biologic window for chimeric L6 radioimmunotherapy, <i>Cancer</i> 73(3):1023-32 (1994)  |  |  |
|  | Dickson, Scientists produce chimeric monoclonal abs, <i>Genetic Engineering News</i> 5/3 (March 1985).   |  |  |
|  | Eary, J.F. et al, Imaging and Treatment of B-Cell Lymphoma, <i>J. Nuc. Med.</i> 31/8:1257-1268 (1990).   |  |  |
|  | Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, <i>EMBO</i> 7:711 (1988)   |  |  |
|  | Golay, J.T., et al., The CD20 (Bp35) antigen is involved in activation of B cells from the G <sub>0</sub> to the G <sub>1</sub> phase of the cell cycle, <i>J. Immunology</i> 135(6):3795-3801 (1985)  |  |  |
|  | Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, <i>J. Clin. Onc.</i> 9/4:548-564 (1991).   |  |  |
|  | Greenberger, J.S., et al., Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture, <i>Cancer Research</i> 45:758-767 (1985)  |  |  |
|  | Hekman, A., et al., Immunotherapy, The Netherlands Cancer Institute Amsterdam Annual Report, pp. 47-48 (1993)  |  |  |
|  | Lipton, J.M., et al., Distribution of B1, calla, $\beta$ 2 microglobulin and Ia on hematopoietic progenitors and hematopoiesis supporting cells (HSC) in short and long-term cultures, <i>Blood</i> , 60(5) (Suppl. 1):170a (Abstract 609) (1982)                |  |  |
|  | Kaminski, M.G. et al., "Radioimmunotherapy of B-cell lymphoma with [ <sup>131</sup> I] anti-B1 (anti-CD20) antibody, <i>NEJM</i> 329/7 (1993).   |  |  |
|  | Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. <i>J. Immun.</i> 139/10:3521-3526 (1987).   |  |  |
|  | Marx, Antibodies made to order, <i>Science</i> 229 455 (August 1985).  |  |  |
|  | Morrison, S.L., et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <i>PNAS</i> 81:6851-6854 (November 1984).   |  |  |
|  | Morrison, Transfectomas provide novel chimeric antibodies, <i>Science</i> 229:1202-1207 (September 1985).  |  |  |
|  | Munro, Uses of chimaeric antibodies, <i>Nature</i> 312:597 (December 1984).  |  |  |
|  | Nadler, L.M., et al., B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation, <i>J. Clin. Invest.</i> 74:332-340 (1984)  |  |  |

M L

8/31/02

PAT-1449 12/9870048313v1

O P F  
V3  
PATENT & TRADEMARK OFFICE  
U.S. DEPARTMENT OF COMMERCE

|   |  |  |  |
|---|--|--|--|
| Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, <i>The Lancet</i> , Vol. II, pp. 427-431 (1984)  |  |  |  |
| Nadler, L.M., et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, <i>Cancer Research</i> , 40:3147-3154 (1980)  |  |  |  |
| Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, <i>Nature</i> 314:268 (March 1985).  |  |  |  |
| Oettgen, H.C., et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2, <i>Hybridoma</i> , 2(1):17-28 (1983)   |  |  |  |
| Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2 <sup>b</sup> haplotype reveal genetic control of isotype expression, <i>J. Immunology</i> , 126(1):317-321 (1981)  |  |  |  |
| Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)  |  |  |  |
| Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).   |  |  |  |
| Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)  |  |  |  |
| Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>J. Cellular Biochem., Suppl.</i> 17E:260 (Abstract T103) (1993)   |  |  |  |
| Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>Blood</i> , 83(2):435-445 (1994)  |  |  |  |
| Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, <i>Blood</i> , 79(9):2229-2236 (1992) |  |  |  |
| Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).   |  |  |  |
| Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).  |  |  |  |
| Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).  |  |  |  |
| Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, <i>J. Natl. Cancer Inst.</i> , 82(9):763-771 (1990)  |  |  |  |
| Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).   |  |  |  |
| Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, <i>J. Immunology</i> , 138(10):3179-3184 (1987)  |  |  |  |
| Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).  |  |  |  |
| Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).  |  |  |  |
| Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).   |  |  |  |
| Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, <i>J. Immunology</i> , 135(2):973-979 (1985)  |  |  |  |
| Urbaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell &amp; Mol. Gen.</i> 12/6:555-566 (1986).  |  |  |  |
| Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).  |  |  |  |
| Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, <i>Med. Phys.</i> , 11(5):638-645 (1984)   |  |  |  |

Examiner

Date Considered: 8/31/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.